Autor: |
Arghya Ray, Ting Du, Xueping Wan, Yan Song, Sindhu C. Pillai, Md. Abu Musa, Teng Fang, Jared Moore, Brian Blank, Xiaohui Du, Xi Chen, Robert Warne, Dena Sutimantanapi, Fang Lui, Tatiana Zavorotinskaya, Christophe Colas, Lori Friedman, Melissa R. Junttila, Dharminder Chauhan, Kenneth C. Anderson |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-6 (2024) |
Druh dokumentu: |
article |
ISSN: |
2044-5385 |
DOI: |
10.1038/s41408-024-01019-5 |
Popis: |
Highlights CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144). |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|